TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27082736
Drug: Intravitreal injections
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injections of anti-VEGF drugs (ranibizumab and/or aflibercept)
Study: 27082736
Drug: Cumulative number
Normalized name: Derma Numb
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cumulative number of aflibercept injections
Study: 27082736
Drug: Cumulative number
Normalized name: Derma Numb
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cumulative number of intravitreal injections of overall anti-VEGF drugs
Study: 19786130
Drug: SB-423557 (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB-423557 (daily oral administration)
Study: 19786130
Drug: SB-423562 (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB-423562 (single intravenous dose)
Study: 19786130
Drug: SB-423557 (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB-423557 (single oral dose)
Study: 19786130
Drug: SB-423557 (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB-423557 (higher doses)
Study: 17479288
Drug: Topotecan (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan (1.0 mg/m(2)/day 168‐h continuous infusion), cyclophosphamide (100 mg/m(2)/day 1‐h infusion days 1‐7), etoposide (100 mg/m(2)/day 1‐h infusion days 8‐10)
Study: 15209391
Drug: Vaginal washing
Normalized name: Zencia Wash
DrugBank: Octasulfur (DB09353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal washing with povidone iodine and insertion of chloramphenicol vaginal tablets in women with IL-8 elevations (Group B)
Study: 15209391
Drug: Not applicable
Normalized name: AIR 1000 mL in 1 L NOT APPLICABLE GAS
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not applicable (Group A, no treatment)
Study: 15209391
Drug: Not applicable
Normalized name: AIR 1000 mL in 1 L NOT APPLICABLE GAS
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not applicable (Group C, treatment not specified)
Study: 9830832
Drug: L-glutamine (GLN)
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-glutamine (GLN) 0.03 g.kg body mass‐1
Study: 9830832
Drug: L-glutamine (GLN)
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-glutamine (GLN)
Study: 2724486
Drug: Psyllium hydrophilic
Normalized name: PSYLLIUM HYDROPHILIC MUCILLOID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psyllium hydrophilic mucilloid (3.4 g three times per day for 8 weeks)
Study: 25311913
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of DF and SMM
Study: 16965776
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg and placebo
Study: 16965776
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg and ramipril 10 mg
Study: 16965776
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (simvastatin 20 mg and ramipril 10 mg)
Study: 7486293
Drug: Extrapleural analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extrapleural analgesia with 20 mL of 0.5% bupivacaine
Study: 7486293
Drug: Intrpleural analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrpleural analgesia with 20 mL of 0.5% bupivacaine
Study: 3148149
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate (800 mg)
Study: 6958473
Drug: Inhaled terbutaline
Normalized name: terbutaline Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled terbutaline pretreatment
Study: 15785303
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) 4 IU every other day for 3 months
Study: 11989050
Drug: Intravenous ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketorolac 60 mg i.v. 30 min before ESWL
Study: 11989050
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl 100 micrograms i.v. 3 min before ESWL
Study: 9803444
Drug: Antenatal TRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antenatal TRH treatment
Study: 2551765
Drug: Ursodeoxycholic acid,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid, 10 mg/kg.day
Study: 31349003
Drug: Doxycycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (100 mg daily once or twice based on BMI) as an add-on to standard therapy
Study: 31349003
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (SAMA + SABA inhaled and ICS + LABA or ICS + LABA + LAMA)
Study: 25514794
Drug: Rosuvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (10 mg daily)
Study: 21109771
Drug: Azacitidine (AZA)
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine (AZA) and Valproic Acid (VPA) combination therapy
Study: 21173560
Drug: Clevudine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clevudine (30 mg once daily for more than 48 weeks)
Study: 21173560
Drug: Entecavir (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entecavir (0.5 mg once daily for more than 48 weeks)
Study: 21173560
Drug: Lamivudine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine (100 mg once daily for more than 48 weeks)
Study: 12009718
Drug: Urate concentration
Normalized name: Urate oxidase
DrugBank: Rasburicase (DB00049)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Urate concentration greater than 0.31 mmol.l(-1)
Study: 12009718
Drug: Urate concentration
Normalized name: Urate oxidase
DrugBank: Rasburicase (DB00049)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Urate concentration greater than 0.38 mmol.l(-1)
Study: 12009718
Drug: Raised urate
Normalized name: Urate oxidase
DrugBank: Rasburicase (DB00049)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Raised urate in patients not on diuretics
Study: 7843758
Drug: Amlodipine and
Normalized name: amlodipine and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine and Lisinopril
Study: 2588996
Drug: 1:200,000 epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1:200,000 epinephrine with 10 ml of 1.5% lidocaine
Study: 22093196
Drug: Saxagliptin 5
Normalized name: sAXagliptin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saxagliptin 5 mg QD (2.5 mg in subjects with moderate/severe renal impairment)
Study: 15563390
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment (extended lateral approach with subchondral fixation, plating, and bone grafting when necessary)
Study: 15563390
Drug: Nonoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative treatment (ice, elevation, and rest without closed reduction)
Study: 9153347
Drug: Fasting administration
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting administration of 400 mg racemic ibuprofen
Study: 9153347
Drug: Postprandial administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postprandial administration of 400 mg racemic ibuprofen
Study: 3608379
Drug: Chlorpropamide 250
Normalized name: chlorpropamide 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpropamide 250 mg twice daily for 2 days
Study: 29460783
Drug: Glucose 25
Normalized name: glucose 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose 25 g
Study: 25658956
Drug: Tasimelteon 20
Normalized name: tasimelteon 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tasimelteon 20 mg capsule
Study: 25658956
Drug: Tasimelteon 2
Normalized name: tasimelteon 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tasimelteon 2 mg IV infusion over 30 minutes
Study: 25658956
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (oral and IV)
Study: 20377407
Drug: Reduced-dose (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced-dose (9 microg, 0.3 mL) ID injection
Study: 20377407
Drug: Reduced-dose (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced-dose (9 microg, 0.3 mL) IM injection
Study: 20377407
Drug: Standard-dose (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose (15 microg each of 3 hemagglutinin vaccine antigens in 0.5 mL) IM injection
Study: 20377407
Drug: Two reduced-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two reduced-dose (4.5 microg, 0.15 mL) ID injections
Study: 18540358
Drug: Apheresis therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apheresis therapy (Plasmapheresis and Cytapheresis)
Study: 16796986
Drug: 21/7 oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21/7 oral contraceptive regimen
Study: 15084614
Drug: ATRA and
Normalized name: ATRA
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ATRA and chemotherapy (CT)
Study: 8319667
Drug: Iron-enriched milk
Normalized name: iron succinyl milk protein complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-enriched milk (12 mg/l)
Study: 8319667
Drug: Control milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control milk (1 mg/l)
Study: 30995895
Drug: Half saline-bicarbonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half saline-bicarbonate infusion
Study: 30146142
Drug: ePST (computer-guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: ePST (computer-guided Problem-Solving Treatment)
Study: 27236864
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of intravenous acetaminophen every 6 hours for 24 hours
Study: 22158433
Drug: Valsartan (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (160 mg/d)
Study: 15841830
Drug: Dialectical behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialectical behavior therapy for depressed older adults
Study: 8830068
Drug: Clonidine plus
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine plus haloperidol (20 mg/day)
Study: 2919772
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine + 2 mg butorphanol
Study: 2919772
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine + 0 mg butorphanol
Study: 2919772
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine + 3 mg butorphanol
Study: 31996813
Drug: 0.3% NaCl
Normalized name: LVP solution Dextrose 5% with 0.3% NaCl intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3% NaCl solution with 0.3% MSG
Study: 31996813
Drug: 0.6% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6% NaCl solution with 0.3% MSG
Study: 31996813
Drug: 0.9% NaCl
Normalized name: Trace Metals Additive in 0.9% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% NaCl solution with 0.3% MSG
Study: 31996813
Drug: 0.3% NaCl
Normalized name: LVP solution Dextrose 5% with 0.3% NaCl intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3% NaCl solution without MSG
Study: 31996813
Drug: 0.6% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6% NaCl solution without MSG
Study: 31996813
Drug: 0.9% NaCl
Normalized name: Trace Metals Additive in 0.9% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% NaCl solution without MSG
Study: 28708734
Drug: 0.1‐mmol/kg bw
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1‐mmol/kg bw of gadoterate (full dose)
Study: 28708734
Drug: 0.05‐mmol/kg bw
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05‐mmol/kg bw of gadobenate (half dose)
Study: 25089928
Drug: Cangrelor infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cangrelor infusion (bolus plus 2-h infusion)
Study: 25089928
Drug: Prasugrel (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel (60 mg dose at 1h, 1.5h, 2h, or 2.5h after cangrelor)
Study: 25089928
Drug: Prasugrel (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel (10 mg daily for 5 or 6 days)
Study: 25089928
Drug: Cangrelor infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cangrelor infusion (on study day 8)
Study: 19341849
Drug: One cycle
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One cycle of pills at initiation, followed by counseling and a three-pack resupply
Study: 11695951
Drug: Melatonin 10
Normalized name: melatonin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 10 mg/d for 6 weeks
Study: 9663244
Drug: Autotransplantation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autotransplantation of 60 mg of a diffuse hyperplastic parathyroid gland into subcutaneous forearm tissue (Group A)
Study: 9663244
Drug: Autotransplantation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autotransplantation of 15 pieces (60 mg) of 1 mm3 tissue into forearm muscles (Group B)
Study: 15613018
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg quercetin‐4'‐O‐beta‐D‐glucoside
Study: 15613018
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg quercetin‐4'‐O‐beta‐D‐glucoside
Study: 10637204
Drug: Intra-arterial infusion
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial infusion of carbachol
Study: 10637204
Drug: Intra-arterial infusion
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial infusion of L-NMMA
Study: 10637204
Drug: Intra-arterial infusion
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial infusion of carbachol followed by coinfusion with L-NMMA
Study: 9314339
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (ragweed immunotherapy)
Study: 9314339
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (initial immunotherapy)
Study: 28257614
Drug: Cortisone Injection
Normalized name: hydrocortisone Injection
DrugBank: Cortisone (DB14681)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisone Injection
Study: 28257614
Drug: Medication intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication intake for pain
Study: 25361981
Drug: Low-ER receptor
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-ER receptor signaling and apoptosis gene module scores
Study: 24289059
Drug: New Medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: New Medicine Service (NMS) intervention comprising pharmacist-delivered support for a newly prescribed medicine
Study: 21828126
Drug: High-dose daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose daunorubicin (HD-DN, 90 mg/m² per day times 3 days)
Study: 21828126
Drug: Standard-dose daunorubicin
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard-dose daunorubicin (SD-DN, 45 mg/m² per day times 3 days)
Study: 21828126
Drug: High-dose daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose daunorubicin (HD-DN)
Study: 21828126
Drug: Standard-dose daunorubicin
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard-dose daunorubicin (SD-DN)
Study: 9340641
Drug: Alcohol (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (1.5 ml per kg of body weight of 80 proof vodka)
Study: 8343351
Drug: No complementary
Approvals — FDA: no, EMA: no, PMDA: no
Description: No complementary treatment (Control)
Study: 28976265
Drug: Gr.Suppl.5 -
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gr.Suppl.5 - 5 µg daily dose of VitD3-fortified yogurt
Study: 28976265
Drug: Gr.Suppl.10 -
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gr.Suppl.10 - 10 µg daily dose of VitD3-fortified yogurt
Study: 18395907
Drug: Prepacol (sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prepacol (sodium phosphate and bisacodyl) preparation in 26 patients
Study: 18395907
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no Prepacol preparation) in 26 patients
Study: 15562015
Drug: Calcium (500
Normalized name: calcium gluconate 45 mg calcium (500 mg) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (500 mg twice daily with meals)
Study: 9798657
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (Group A, n = 11)
Study: 869086
Drug: Smoking withdrawal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking withdrawal clinic protocols (various drugs and education methods)
Study: 30959006
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam 0.2 mg/kg (group MD)
Study: 30959006
Drug: Oral melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral melatonin 0.4 mg/kg (group M)
Study: 30959006
Drug: Oral multivitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral multivitamin tablet as placebo (group P)
Study: 29336763
Drug: Daily chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily chlorhexidine gluconate (CHG) baths and mupirocin (MUP) ointment to the nares
Study: 29336763
Drug: Soap and
Normalized name: Green soap and industrial methylated spirit only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soap and water baths and placebo ointment
Study: 24517052
Drug: Xinfeng Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xinfeng Capsule (XC) 3 tablets thrice daily for 12 weeks
Study: 24517052
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (routine anti‐rheumatic treatment: Methotrexate 10 mg/week; Diclofenac 50 mg twice daily when pain was obvious)
Study: 16638738
Drug: BAY 59-7939
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 59-7939 (rivaroxaban) 5 mg tablets (fasted and fed)
Study: 16638738
Drug: BAY 59-7939
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 59-7939 (rivaroxaban) 10 mg
Study: 16638738
Drug: BAY 59-7939
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 59-7939 (rivaroxaban) 20 mg
Study: 16638738
Drug: BAY 59-7939
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 59-7939 (rivaroxaban) with ranitidine (150 mg twice daily)
Study: 16638738
Drug: BAY 59-7939
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 59-7939 (rivaroxaban) with antacid (10 mL)
Study: 15598997
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A - initial conservative treatment followed by interval appendectomy six weeks later
Study: 15598997
Drug: Group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C - conservative treatment alone
Study: 9709410
Drug: Substance P
Normalized name: Substance P
DrugBank: Substance P (DB19198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substance P (2-8 pmol/min) with L-NMMA (1-4 micrograms/min)
Study: 9709410
Drug: L-NMMA (1-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA (1-4 micrograms/min) alone
Study: 2919798
Drug: Potassium metabisulfite
Normalized name: Potassium Metabisulfite
DrugBank: Potassium metabisulfite (DB15841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium metabisulfite oral aqueous challenge
Study: 16329464
Drug: cis-9,trans-11 CLA
Approvals — FDA: no, EMA: no, PMDA: no
Description: cis-9,trans-11 CLA (3 g/day)
Study: 16329464
Drug: trans-10,cis-12 CLA
Approvals — FDA: no, EMA: no, PMDA: no
Description: trans-10,cis-12 CLA (3 g/day)
Study: 12410740
Drug: Nocturia (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nocturia (mean of twice or more/night)
Study: 12410740
Drug: Age, poor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Age, poor health status, and use of medication
Study: 10421262
Drug: Postoperative radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative radiotherapy at a total dose of 60 gray
Study: 7669462
Drug: Interscalene brachial
Normalized name: Brachiara mutica pollen
DrugBank: Urochloa mutica pollen (DB10716)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interscalene brachial plexus block with 0.5% bupivacaine and adrenaline 1/200,000 40 ml with the addition of morphine 5 mg
Study: 7669462
Drug: Interscalene brachial
Normalized name: Brachiara mutica pollen
DrugBank: Urochloa mutica pollen (DB10716)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interscalene brachial plexus block with 0.5% bupivacaine and adrenaline 1/200,000 40 ml alone
Study: 2401752
Drug: Ticlopidine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine (250 mg) administered after food
Study: 2401752
Drug: Ticlopidine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine (250 mg) administered after antacid
Study: 2401752
Drug: Ticlopidine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine (250 mg) administered in fasting conditions
Study: 7434079
Drug: Quinacrine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinacrine (100 mg t.i.d. for 5 days)
Study: 7434079
Drug: Metronidazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (200 mg t.i.d. for 7 days)
Study: 7434079
Drug: Metronidazole (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (2 gm single dose)
Study: 7434079
Drug: Tinidazole (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinidazole (2 gm single dose)
Study: 7434079
Drug: Ornidazole (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ornidazole (2 gm single dose)
Study: 6134959
Drug: Ceftriaxone 125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 125 mg IM
Study: 23639952
Drug: Group music
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group music therapy (12 sessions, two 30-min sessions per week for 6 weeks)
Study: 22495183
Drug: Oxycodone 5
Normalized name: oxycodone 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 5 mg/70 kg
Study: 22495183
Drug: Oxycodone 20
Normalized name: oxycodone 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 20 mg/70 kg
Study: 22495183
Drug: Oxycodone (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone (daily administration)
Study: 22495183
Drug: Oxycodone (intermittent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone (intermittent administration)